Radionuclide brain imaging correlates of cognitive impairment in Parkinson's disease (PD).

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Neurological Sciences

• Publication date

  2011-11-15

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.jns.2011.06.053PMID 21762928
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia

  2010cited by this paper
• Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo

  2010influential reference
• Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease.

  2010cited by this paper
• Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes

  2010cited by this paper
• Dementia in Lewy body syndromes

  2010cited by this paper
• Cognitive‐nigrostriatal relationships in de novo, drug‐naïve Parkinson's disease patients: A [I‐123]FP‐CIT SPECT study

  2010cited by this paper
• Amnestic mild cognitive impairment in Parkinson's disease: A brain perfusion SPECT study

  2009cited by this paper
• Artefactual subcortical hyperperfusion in PET studies normalized to global mean: Lessons from Parkinson's disease

  2009cited by this paper
• Decrease of Nicotinic Receptors in the Nigrostriatal System in Parkinson's Disease

  2009cited by this paper
• Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET

  2009cited by this paper
• Changes in Cerebral Glucose Metabolism in Patients with Parkinson Disease with Dementia After Cholinesterase Inhibitor Therapy

  2008cited by this paper
• Imaging amyloid deposition in Lewy body diseases

  2008cited by this paper
• Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease

  2008cited by this paper
• Cognitive deficits and striato-frontal dopamine release in Parkinson's disease.

  2008cited by this paper
• The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation

  2007cited by this paper
• Defining mild cognitive impairment in Parkinson's disease

  2007influential reference
• Metabolic brain networks associated with cognitive function in Parkinson's disease

  2007cited by this paper
• Frontal Assessment Battery and Brain Perfusion Image in Parkinson’s Disease

  2006cited by this paper
• Molecular imaging of the dopaminergic system and its association with human cognitive function.

  2006cited by this paper
• Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson’s disease

  2005cited by this paper
• Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease.

  2005cited by this paper
• Cognitive and SPECT characteristics predict progression of Parkinson’s disease in newly diagnosed patients

  2004cited by this paper
• Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies

  2004cited by this paper
• Statistical parametric mapping of (99m)Tc-ECD SPECT in idiopathic Parkinson's disease and multiple system atrophy with predominant parkinsonian features: correlation with clinical parameters.

  2004cited by this paper
• Regional cerebral blood flow in Parkinson's disease with and without dementia

  2003cited by this paper
• Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study.

  2003cited by this paper
• Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study.

  2002cited by this paper
• Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity.

  1997cited by this paper
• Dopamine visualized in the basal ganglia of living man

  1983cited by this paper

• Biochemical properties and biological potential of Syzygium heyneanum with antiparkinson’s activity in paraquat induced rodent model

  2024cites this paper
• Pathological Correlates of Cognitive Decline in Parkinson’s Disease: From Molecules to Neural Networks

  2023cites this paper
• Validation of dynamic [18F]FE-PE2I PET for estimation of relative regional cerebral blood flow: a comparison with [15O]H2O PET

  2022cites this paper
• QEEG indices are associated with inflammatory and metabolic risk factors in Parkinson's disease dementia: An observational study

  2022cites this paper
• Metabolic correlates of olfactory dysfunction in COVID-19 and Parkinson’s disease (PD) do not overlap

  2022cites this paper
• Lewy Body Dementias: A Coin with Two Sides?

  2021cites this paper
• Biomarker detection of Parkinson’s disease: therapy and treatment using nanomaterials

  2020cites this paper
• Magnetic resonance spectroscopy in Parkinson’s disease

  2020cites this paper
• Neuroimaging Findings in Mild Cognitive Impairment

  2020cites this paper
• Combined 18F-fluorodeoxyglucose positron emission tomography and event-related potentials study of the cognitive impairment mechanisms in Parkinson's disease.

  2019cites this paper
• The effect of small vessel disease on motor and cognitive function in Parkinson's disease.

  2019cites this paper
• Возможности магнитно-резонансной спектроскопии при болезни Паркинсона

  2019cites this paper
• Dopamine D2 Receptor Radiopharmaceutical: I-123-Epidepride Toxicology and Preclinical SPECT Image

  2018cites this paper
• [Characteristics of cerebral glucose metabolism in patients with cognitive impairment in Parkinson's disease].

  2017cites this paper
• Accelerated Age-Dependent Hippocampal Volume Loss in Parkinson Disease With Mild Cognitive Impairment

  2017cites this paper
• Recent Progress of Imaging Agents for Parkinson's Disease

  2014cites this paper
• PET probes for imaging brain acetylcholinesterase.

  2013cites this paper
• Idiopathic Parkinson's Disease, Vascular Risk Factors and Cognition: A Critical Review

  2012cites this paper
• Visualizing Sweetness: Increasingly Diverse Applications for Fluorescent-Tagged Glucose Bioprobes and Their Recent Structural Modifications

  2012cites this paper
• Long-term neurotoxic effects of dimethylamine borane intoxication.

  2012cites this paper